Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.
Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M. Hartman L, et al. Scand J Rheumatol. 2019 Jul;48(4):340-341. doi: 10.1080/03009742.2018.1559880. Epub 2019 May 27. Scand J Rheumatol. 2019. PMID: 31132016 No abstract available.
Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, Boers M. Hartman L, et al. Trials. 2018 Jan 25;19(1):67. doi: 10.1186/s13063-017-2396-3. Trials. 2018. PMID: 29370811 Free PMC article.
Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count.
Hartman L, Cutolo M, Bos R, Opris-Belinski D, Kok MR, Griep-Wentink HJRM, Klaasen R, Allaart CF, Bruyn GAW, Raterman HG, Voshaar MJH, Gomes N, Pinto RMA, Klausch LT, Lems WF, Boers M. Hartman L, et al. Rheumatology (Oxford). 2021 Nov 3;60(11):5239-5246. doi: 10.1093/rheumatology/keab207. Rheumatology (Oxford). 2021. PMID: 33682887 Free PMC article. Clinical Trial.
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, Griep EN, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Klausch LT, Paolino S, Schilder AM, Lems WF, Cutolo M; GLORIA Trial consortium. Boers M, et al. Among authors: hartman l. Ann Rheum Dis. 2022 Jul;81(7):925-936. doi: 10.1136/annrheumdis-2021-221957. Epub 2022 May 31. Ann Rheum Dis. 2022. PMID: 35641125 Free PMC article. Clinical Trial.
Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.
Hartman L, da Silva JAP, Buttgereit F, Cutolo M, Opris-Belinski D, Szekanecz Z, Masaryk P, Voshaar MJH, Heymans MW, Lems WF, van der Heijde DMFM, Boers M. Hartman L, et al. Rheumatology (Oxford). 2023 May 2;62(5):1824-1833. doi: 10.1093/rheumatology/keac547. Rheumatology (Oxford). 2023. PMID: 36165675 Free PMC article. Clinical Trial.
Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.
Hartman L, Rasch LA, Turk SA, Ter Wee MM, Kerstens PJSM, van der Laken CJ, Nurmohamed MT, van Schaardenburg D, van Tuyl LHD, Voskuyl AE, Boers M, Lems WF. Hartman L, et al. Rheumatology (Oxford). 2023 Jun 1;62(6):2098-2105. doi: 10.1093/rheumatology/keac582. Rheumatology (Oxford). 2023. PMID: 36205538 Free PMC article. Clinical Trial.
Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.
Hartman L, El Alili M, Cutolo M, Opris D, Da Silva J, Szekanecz Z, Buttgereit F, Masaryk P, Bos R, Kok MR, Paolino S, Coupé V, Lems WF, Boers M; GLORIA consortium. Hartman L, et al. Semin Arthritis Rheum. 2022 Dec;57:152109. doi: 10.1016/j.semarthrit.2022.152109. Epub 2022 Oct 21. Semin Arthritis Rheum. 2022. PMID: 36335684 Free article. Clinical Trial.
Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.
Palmowski A, Nielsen SM, Boyadzhieva Z, Schneider A, Pankow A, Hartman L, Da Silva JAP, Kirwan J, Wassenberg S, Dejaco C, Christensen R, Boers M, Buttgereit F. Palmowski A, et al. Among authors: hartman l. Rheumatology (Oxford). 2023 Aug 1;62(8):2652-2660. doi: 10.1093/rheumatology/kead088. Rheumatology (Oxford). 2023. PMID: 36810945
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
Almayali AAH, Boers M, Hartman L, Opris D, Bos R, Kok MR, Da Silva JA, Griep E, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Lems W, Smulders Y, Cutolo M, Ter Wee MM. Almayali AAH, et al. Among authors: hartman l. Ann Rheum Dis. 2023 Oct;82(10):1307-1314. doi: 10.1136/ard-2023-223977. Epub 2023 Aug 4. Ann Rheum Dis. 2023. PMID: 37541762 Clinical Trial.
252 results